Single Dose RVSVΔG-JUNVGP Vaccine Protects Guinea Pigs Against Lethal Junin Virus Challenge

Overview

Journal NPJ Vaccines

Date 2021 Aug 10

PMID 34373461

Authors

Teresa E Sorvillo

Robert W Cross

Dylan M Johnson

Natalie S Dobias

Karla A Fenton

Chad E Mire

Thomas W Geisbert

Affiliations

Soon will be listed here.

Abstract

Junin virus (JUNV) is a pathogen of biodefense importance due to its potential for aerosol transmission and mortality rates reaching 30%. Currently, there are no JUNV vaccines licensed by the United States Food and Drug Administration (FDA) for at-risk individuals. A vaccine based on recombinant vesicular stomatitis virus (rVSV) has been effectively used to prevent Ebola virus disease in humans. Here, we evaluated the protective efficacy of a rVSV expressing the JUNV glycoprotein (rVSVΔG-JUNVGP) in a guinea pig model of lethal JUNV disease. Two groups of guinea pigs, one prime and one prime-boost, were vaccinated with rVSVΔG-JUNVGP; six control animals remained unvaccinated. Survival for prime and prime-boost vaccinated animals was 100% while the challenge virus was uniformly lethal in all control animals. Animals in both vaccine groups developed robust, high avidity IgG antibody titers post-vaccination as well as detectable neutralizing antibodies while control animals failed to develop detectable antibody responses. This study demonstrates for the first time that rVSV expressing the JUNV GP fully protects guinea pigs from lethal JUNV challenge with a single injection vaccine.

References

McKee Jr K, Huggins J, Trahan C, MAHLANDT B . Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother. 1988; 32(9):1304-9. PMC: 175856. DOI: 10.1128/AAC.32.9.1304. View

Enria D, Briggiler A, Fernandez N, Levis S, MAIZTEGUI J . Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984; 2(8397):255-6. DOI: 10.1016/s0140-6736(84)90299-x. View

Kenyon R, Condie R, Jahrling P, Peters C . Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb Pathog. 1990; 9(4):219-26. DOI: 10.1016/0882-4010(90)90010-n. View

Enria D, BARRERA ORO J . Junin virus vaccines. Curr Top Microbiol Immunol. 2002; 263:239-61. DOI: 10.1007/978-3-642-56055-2_12. View

Golden J, Maes P, Kwilas S, Ballantyne J, Hooper J . Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever. J Virol. 2016; 90(7):3515-29. PMC: 4794662. DOI: 10.1128/JVI.02969-15. View

Albarino C, Bird B, Chakrabarti A, Dodd K, White D, Bergeron E . Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains. J Virol. 2010; 85(1):112-22. PMC: 3014187. DOI: 10.1128/JVI.01837-10. View

Mire C, Geisbert J, Versteeg K, Mamaeva N, Agans K, Geisbert T . A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs. J Infect Dis. 2015; 212 Suppl 2:S384-8. PMC: 4564539. DOI: 10.1093/infdis/jiv126. View

Enria D, MAIZTEGUI J . Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994; 23(1):23-31. DOI: 10.1016/0166-3542(94)90030-2. View

Weissenbacher M, Calello M, Merani M, McCormick J, Rodriguez M . Therapeutic effect of the antiviral agent ribavirin in Junín virus infection of primates. J Med Virol. 1986; 20(3):261-7. DOI: 10.1002/jmv.1890200308. View

10.

Enria D, Ambrosio A, Briggiler A, Feuillade M, Crivelli E . [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety]. Medicina (B Aires). 2010; 70(3):215-22. View

11.

MAIZTEGUI J, McKee Jr K, BARRERA ORO J, Harrison L, Gibbs P, Feuillade M . Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis. 1998; 177(2):277-83. DOI: 10.1086/514211. View

12.

Schnell M, Buonocore L, Kretzschmar E, Johnson E, Rose J . Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A. 1996; 93(21):11359-65. PMC: 38062. DOI: 10.1073/pnas.93.21.11359. View

13.

Rodriguez S, Cross R, Fenton K, Bente D, Mire C, Geisbert T . Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Sci Rep. 2019; 9(1):7755. PMC: 6533279. DOI: 10.1038/s41598-019-44210-6. View

14.

Geisbert T, Feldmann H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011; 204 Suppl 3:S1075-81. PMC: 3218670. DOI: 10.1093/infdis/jir349. View

15.

Weissenbacher M, de Guerrero L, Boxaca M . Experimental biology and pathogenesis of Junin virus infection in animals and man. Bull World Health Organ. 1975; 52(4-6):507-15. PMC: 2366619. View

16.

Burri D, da Palma J, Kunz S, Pasquato A . Envelope glycoprotein of arenaviruses. Viruses. 2012; 4(10):2162-81. PMC: 3497046. DOI: 10.3390/v4102162. View

17.

Brown K, Safronetz D, Marzi A, Ebihara H, Feldmann H . Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011; 85(23):12781-91. PMC: 3209372. DOI: 10.1128/JVI.00794-11. View

18.

Weissenbacher M, LASCANO E, Avila M, Berria M . Chronic neurologic disease in Junín virus-infected rats. J Med Virol. 1986; 20(1):57-65. DOI: 10.1002/jmv.1890200108. View

19.

Sanchez A, Pifat D, Kenyon R, Peters C, McCormick J, Kiley M . Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol. 1989; 70 ( Pt 5):1125-32. DOI: 10.1099/0022-1317-70-5-1125. View

20.

Henao-Restrepo A, Camacho A, Longini I, Watson C, Edmunds W, Egger M . Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2016; 389(10068):505-518. PMC: 5364328. DOI: 10.1016/S0140-6736(16)32621-6. View